|
gptkbp:instanceOf
|
gptkb:chemical_compound
gptkb:drug
|
|
gptkbp:approvalYear
|
2013
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
gptkb:L04AX07
|
|
gptkbp:brand
|
gptkb:Skilarence
gptkb:Tecfidera
|
|
gptkbp:CASNumber
|
624-49-7
|
|
gptkbp:category
|
gptkb:fumarate_ester
estrogen
immunosuppressant
methyl ester
|
|
gptkbp:chemicalFormula
|
C6H8O4
|
|
gptkbp:contraindication
|
hypersensitivity to dimethyl fumarate
severe gastrointestinal disorders
|
|
gptkbp:eliminationHalfLife
|
~1 hour
|
|
gptkbp:excretion
|
mainly as CO2 via respiration
|
|
gptkbp:firstDescribed
|
1958
|
|
gptkbp:hasInChIKey
|
InChI=1S/C6H8O4/c1-9-5(7)3-4-6(8)10-2/h3-4H,1-2H3/b4-3+
|
|
gptkbp:hasSMILES
|
COC(=O)C=CC(=O)OC
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
dimethyl fumarate
|
|
gptkbp:IUPACName
|
gptkb:dimethyl_(E)-but-2-enedioate
|
|
gptkbp:KEGGID
|
D09913
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
immunotherapy
activates Nrf2 pathway
|
|
gptkbp:meltingPoint
|
103–105 °C
|
|
gptkbp:metabolism
|
hydrolyzed to monomethyl fumarate
|
|
gptkbp:molecularWeight
|
144.13 g/mol
|
|
gptkbp:origin
|
synthetic
|
|
gptkbp:pregnancyCategory
|
C
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1257
gptkb:DB08908
552857
637568
|
|
gptkbp:relatedTo
|
gptkb:monomethyl_fumarate
fumaric acid
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:lymphopenia
flushing
gastrointestinal symptoms
liver enzyme elevation
|
|
gptkbp:solubility
|
slightly soluble in water
soluble in ethanol
|
|
gptkbp:UNII
|
53J7X08Y7N
|
|
gptkbp:usedFor
|
multiple sclerosis
psoriasis
|
|
gptkbp:bfsParent
|
gptkb:Tecfidera
|
|
gptkbp:bfsLayer
|
6
|